Business
Faron Pharmaceuticals Ltd: Notice of Half-Yea...
Faron Pharmaceuticals Ltd. announced that its unaudited half-year financial results for the period January-June 2025 will be released on Wednesday, August 27, 2025. A virtual briefing and Q&A session for investors, analysts, and media will be held at 09:00 am (EDT) / 2:00 pm (BST) / 4:00 pm (EEST) on the same day. The half-year report, presentation, and a webcast replay will be available on the company's website afterward. Disclaimer*
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n\n \n Faron Pharmaceuticals Ltd | Company announcement | August 19, 2025 at 09:00:00 EEST\nFaron Pharmaceuticals will publish its half-year financial results for January-June 2025 on Wednesday 27 August 2025\nTURKU, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, will report its unaudited half-year financial results for the six months ended 30 June 2025, on Wednesday, 27 August 2025.A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Juho Jalkanen, Chief Executive Officer, Yrjö Wichmann, Chief Financial Officer and Dr. Petri Bono, Chief Medical Officer, at 09:00 am (EDT) / 2:00 pm (BST) / 4:00 pm (EEST) on Wednesday, 27 August 2025. Webcast registration link: Faron 2025 Half-Year Financial ResultsThe half-year report, presentation, and a replay of the webcast will be published afterward on the Company's website at: Reports and presentations - FaronFor more information, please contact:Kare Laukkanen+358 50 553 9535 / +44 7 469 766 [email protected] Partners, US (media) Alyssa Paldo +1 847 791-8085 [email protected] Financial Advisers LLP, Nominated Adviser and BrokerSandy Jamieson, Jo TurnerPhone: +44 (0) 207 213 0880Sisu Partners Oy, Certified Adviser on Nasdaq First NorthJuha KarttunenPhone: +358 (0)40 555 4727Jukka JärveläPhone: +358 (0)50 553 8990About bexmarilimabBexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.About Faron Pharmaceuticals Ltd.Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceu...